Short Seller Attacks Safety of Lead UC Drug; Shares Close Down 9%
ABVX sits 19% above its 52-week low of $62.7 on elevated volume (11× avg).
Summary
Scorpion Research published a short report attacking obefazimod, Abivax's ulcerative colitis candidate, claiming the drug is extremely lipophilic — comparable to banned pesticides — and raising the risk of long-term tissue accumulation. Scorpion disclosed it holds a short position. Abivax closed down about 9% on the session, then fired back after the bell, calling the report factually inaccurate and misleading and noting some cited studies were commissioned and funded by Scorpion itself. The company reaffirmed confidence in its Phase 3 ABTECT data and said it still plans a U.S. FDA NDA filing by the end of the year. This is a thesis-level attack on the safety profile of the company's lead asset, not a routine note — the entire equity story rests on obefazimod clearing regulators. The near-term test is whether the NDA submission lands by year-end as promised; any delay or FDA pushback on the safety questions would hit the stock hard.
At the time of this announcement, ABVX was trading at $74.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $62.70 to $148.83. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.